Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic CancerTalia Golan, Hedy L. Kindler, Anke Reinacher‐Schick et al.|New England Journal of Medicine|2019Cited by 2.2k
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerHedy L. Kindler, Talia Golan, Pascal Hammel et al.|Journal of Clinical Oncology|2022Cited by 224
Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.Talia Golan, Hedy L. Kindler, Pascal Hammel et al.|Journal of Clinical Oncology|2021Cited by 78
Geographic and Ethnic Heterogeneity of Germline <i>BRCA1</i> or <i>BRCA2</i> Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO TrialTalia Golan, Michael J. Hall, Hedy L. Kindler et al.|Journal of Clinical Oncology|2020Cited by 73
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparibP. Hammel, Talia Golan, Hedy L. Kindler et al.|Annals of Oncology|2019Cited by 44